[Prostate and Bladder Cancer: Detection of Disseminated Tumor Cells in Bone Marrow]

Overview

Journal Urologe A

Specialty Urology

Date 2014 Mar 28

PMID 24671250

Citations 2

Authors

R Nawroth

D Weckermann

M Retz

Affiliations

Soon will be listed here.

Abstract

The prognosis of prostate and bladder cancer patients is predominantly determined by the detection of distant sites of metastasis. In clinical routine, virtually only lymph node staging is of relevance to determine metastasis. Detection and characterization of disseminated tumor cells in peripheral blood or bone marrow is an additional parameter of prognostic significance. In this article, we will summarize recent progress on the prognostic value of disseminated tumor cells in bone marrow and its translation into routine clinical analysis.

Citing Articles

Advancing Cancer Research and Medicine with Single-Cell Genomics.

Lim B, Lin Y, Navin N Cancer Cell. 2020; 37(4):456-470.

PMID: 32289270 PMC: 7899145. DOI: 10.1016/j.ccell.2020.03.008.

[Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Martini T, Strobel P, Steidler A, Petrakopoulou N, Erben P, Bolenz C Urologe A. 2014; 54(1):70-5.

PMID: 25391439 DOI: 10.1007/s00120-014-3646-6.

References

Taichman R, Patel L, Bedenis R, Wang J, Weidner S, Schumann T . GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One. 2013; 8(4):e61873. PMC: 3634826. DOI: 10.1371/journal.pone.0061873. View

Joseph J, Shiozawa Y, Jung Y, Kim J, Pedersen E, Mishra A . Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res. 2012; 10(3):282-92. PMC: 3307952. DOI: 10.1158/1541-7786.MCR-11-0404. View

Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H . Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27(10):1549-56. DOI: 10.1200/JCO.2008.17.0563. View

Ricci E, Mattei E, Dumontet C, Eaton C, Hamdy F, van der Pluije G . Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate. 2013; 73(16):1738-46. DOI: 10.1002/pros.22689. View

van der Pluijm G . Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone. 2010; 48(1):37-43. DOI: 10.1016/j.bone.2010.07.023. View

Marin-Aguilera M, Mengual L, Ribal M, Ars E, Rios J, Gazquez C . Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology. 2011; 79(1):240.e9-15. DOI: 10.1016/j.urology.2011.09.006. View

Retz M, Lehmann J, Roder C, Weichert-Jacobsen K, Loch T, Romahn E . Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients. Eur Urol. 2001; 39(5):507-15; discussion 516-7. DOI: 10.1159/000052496. View

Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P . Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281(17):1591-7. DOI: 10.1001/jama.281.17.1591. View

Retz M, Rotering J, Nawroth R, Buchner A, Stockle M, Gschwend J . Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol. 2010; 60(2):231-8. DOI: 10.1016/j.eururo.2010.12.014. View

10.

Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G . Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001; 166(2):699-703. View

11.

Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G . Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol. 1999; 17(11):3438-43. DOI: 10.1200/JCO.1999.17.11.3438. View

12.

Murray N, Reyes E, Tapia P, Badinez L, Orellana N . Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an.... Bone Marrow Res. 2012; 2012:259351. PMC: 3513718. DOI: 10.1155/2012/259351. View

13.

Hofmann T, Buchner A, Hofstetter A, Stief C, Oberneder R, Riesenberg R . Prognostic relevance of disseminated tumour cells in bone marrow of patients with transitional cell carcinoma. Eur J Cancer. 2007; 43(18):2678-84. DOI: 10.1016/j.ejca.2007.09.007. View

14.

Hofmann T, Riesenberg R, Buchner A, Zimmermann W, Hofstetter A, Oberneder R . Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators. J Urol. 2003; 169(4):1303-7. DOI: 10.1097/01.ju.0000054917.31718.cd. View

15.

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

16.

Shiozawa Y, Pienta K, Taichman R . Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res. 2011; 17(17):5553-8. PMC: 3593121. DOI: 10.1158/1078-0432.CCR-10-2505. View

17.

Yu C, Shiozawa Y, Taichman R, McCauley L, Pienta K, Keller E . Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr. 2012; 22(2):131-48. PMC: 3615416. DOI: 10.1615/critreveukargeneexpr.v22.i2.50. View

18.

Shiozawa Y, Pedersen E, Havens A, Jung Y, Mishra A, Joseph J . Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011; 121(4):1298-312. PMC: 3069764. DOI: 10.1172/JCI43414. View

19.

Pedersen E, Shiozawa Y, Pienta K, Taichman R . The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian J Androl. 2012; 14(3):423-7. PMC: 3602965. DOI: 10.1038/aja.2011.164. View